ADMA Biologics Announces Upcoming Financial Results
ADMA Biologics, Inc. (NASDAQ: ADMA), a biopharmaceutical company specializing in specialty biologics, has announced its plan to disclose its financial results for the fourth quarter and full year of 2024 on March 3, 2025. The announcement will occur after the closing of the financial markets in the United States, marking an important milestone for the company and its stakeholders.
Live Conference Call Details
On the date of the results announcement, ADMA will host a conference call and audio webcast beginning at 4:30 p.m. ET. This event is intended for investors and analysts, offering insights into the company's performance and future direction. To join the conference call, interested parties can dial (888) 596-4144 and enter the conference ID 5201334. ADMA encourages participants to join approximately 10 minutes before the event to ensure they do not miss any crucial information.
Insight into the Company’s Progress
ADMA Biologics takes pride in manufacturing and marketing three FDA-approved plasma-derived biologics. These products cater specifically to patients with immunodeficiencies, providing vital treatment options. Notable products include ASCENIV™, used for treating primary humoral immunodeficiency, and BIVIGAM, which also addresses immunodeficiency challenges.
Company's Dedication to Quality and Innovation
The company operates state-of-the-art facilities in Boca Raton, Florida, where it focuses on the plasma fractionation and purification processes necessary to create its biologic therapies. ADMA’s commitment extends beyond production; the company continually invests in research to develop innovative solutions for individuals at risk of infections due to weakened immune systems.
FDA-Approved Products
ADMA Biologics manufactures several key products, including NABI-HB, which offers enhanced immunity against the hepatitis B virus. The comprehensive portfolio illustrates the company's mission to provide targeted therapies for niche patient populations.
Gathering of Industry Experts
During the upcoming conference call, ADMA’s management team will not only delve into financial metrics but will also discuss operational updates and future initiatives that will shape the company’s direction. Stakeholders can expect an engaging dialogue that will foster understanding of the challenges and opportunities facing ADMA.
Investor Relations and Communication
ADMA emphasizes the importance of transparency and communication, providing a comprehensive investor relations framework. Interested investors can find further information and resources on ADMA’s official website, which also houses the archived version of the conference call post-event.
Contacting ADMA for More Information
The investor relations team is available for inquiries at Argot Partners, reachable at 212-600-1902. Anyone wishing to discuss potential investment opportunities or seeking further information about ADMA’s operations is encouraged to reach out via email at ADMA@argotpartners.com.
Frequently Asked Questions
What financial results will ADMA Biologics report?
ADMA will report its fourth quarter and full year 2024 financial results.
When will the conference call be held?
The conference call will take place on March 3, 2025, at 4:30 p.m. ET.
How can investors join the conference call?
Investors can join by dialing (888) 596-4144 and entering the conference ID 5201334.
What products does ADMA Biologics manufacture?
ADMA manufactures FDA-approved biologics including ASCENIV™, BIVIGAM, and NABI-HB.
Who should I contact for investor relations inquiries?
For inquiries, you can contact Argot Partners at 212-600-1902 or email ADMA@argotpartners.com.
